VABYSMO (Roche Products Pty Ltd)
Product name
VABYSMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
faricimab
Registration type
NCE/NBE
Indication
VABYSMO is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (nAMD),
- - Diabetic macular oedema (DMO).